Paired with ApoB as the ApoB/ApoA1 ratio, it weighs atherogenic particle burden against protective HDL particles, often tracking cardiovascular risk better than either marker alone.
For atherogenic risk, ApoA1 is best interpreted in context of ApoB, especially as the ApoB/ApoA1 ratio.
Modern lipid guidelines generally do not specify optimal ApoA1 treatment targets; they focus on LDL-C, non-HDL-C, ApoB, Lp(a), and overall ASCVD risk.


About the site author
My personal mission is to extend human lifespan by collectively adding 1 million years to people's lives.
That’s why I made this site 100% free, no sign-up, no email. Just instant results.
Zsolt SzaboPrecision Health Consultant for Longevity Clinics